Abstract
Purpose: The prognosis is dramatic in patients with malignant Schwannoma. These tumours appear to progress invariably irrespective of the complementary treatment given. In order to determine whether this clinical impression is founded, we reviewed retrospectively patients cared for conjointly by the Cochin Hospital and the Curie Institute since 1956.
Material and methods: This series included 32 patients (17 men and 15 women) including seven who had a Recklinghausen neurofibromatosis (three men and four women). The logrank test was used to compare the actuarial survival curves and determine prognostic factors and potential benefit of chemotherapy and radiotherapy protocols.
Results: Mean age at diagnosis was 42.1 years (11.8–78.9). Ten percent of the schwannomas were grade I, 25% grade II and 65% grade III. All patients except two underwent surgery. The resection was considered wide in three cases, marginal in 17, contaminated in seven and non-classifiable in three. There were 14 cases of local recurrence within a mean delay of 12 months (1–66 months). Twelve patients developed secondary local relapse within a mean delay of 36 months (0–169 months). Different neoadjuvant or adjuvant treatments were administered, including chemotherapy and radiotherapy. Twenty-four patients died with a median survival of 25 months. The survival curves showed that complementary treatments did not significantly improve survival. The only factor with prognostic value was the histological grade and the quality of the resection.
Discussion: Our findings are in general agreement with data in the literature demonstrating the lack of efficacy of complementary treatments in patients with malignant schwannomas. Inversely Recklinghausen disease did not appear to modify prognosis in our patients.
The abstracts were prepared by Pr. Jean-Pierre Courpied (General Secretary). Correspondence should be addressed to him at SOFCOT, 56 rue Boissonade, 75014 Paris, France
